Toxicological consequences of Aroclor 1254 ingestion by female rhesus (Macaca mulatta) monkeys. Part 1B. Prebreeding phase: clinical and analytical laboratory findings.
A group of 80 menstruating rhesus (Macaca mulatta) monkeys, with an average estimated age of 11.1 +/- 4.1 yr SD were first randomly allocated to four similar test rooms (20 monkeys/room), and then randomly allocated to one of five dose groups (four females/dose group/room). Each day, the monkeys self-ingested capsules containing doses of 0, 5, 20, 40 or 80 micrograms Aroclor 1254/kg body weight. After 25 months of daily dosing, approximately 90% of the treated females attained a qualitative pharmacokinetic steady state with respect to the concentration of polychlorinated biphenyl (PCB) in their adipose tissue. Subsequently, oestrogen and progesterone concentrations in serum were determined for one complete oestrous cycle and various immunological tests were conducted, while the monkeys continued to receive their daily dose of PCB. During the prebreeding phase of the study, blood for clinical and analytical monitoring including haematology, serum biochemistry, serum hydrocortisone, serum proteins (alpha 1, alpha 2, beta and gamma-globulins), serum immunoglobulins (A, G and M) and thyroid variables (thyroxine/triiodothyronine (T3) uptake ratio, percentage T3 uptake and free thyroxine index), were obtained monthly, as were specimens to ascertain the concentration of PCB in the blood, adipose tissue and faeces. Major findings among treated monkeys included the following: changes in haematology (decreased erythrocyte count, haematocrit, reticulocyte count, and mean platelet volume), serum biochemistry (decreased cholesterol and total bilirubin), immunotoxicity (decreased antibody production to sheep red blood cells and alterations in the percentage of T helper and T suppressor cells) and pathology (the number of regions of sebaceous gland lobules per unit of histological length was significantly reduced). These effects were observed at PCB doses lower than those previously reported for non-human primates.
Arnold
D L
DL
Toxicology Research Division, Bureau of Chemical Safety, Health and Welfare Canada, Ottawa, Ontario.
Bryce
F
F
Karpinski
K
K
Mes
J
J
Fernie
S
S
Tryphonas
H
H
Truelove
J
J
McGuire
P F
PF
Burns
D
D
Tanner
J R
JR
D000273:Adipose Tissue / Q000737:chemistry / Q000378:metabolism*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001140:Aroclors / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D001772:Blood Cell Count; D001773:Blood Cells / Q000187:drug effects*; D001774:Blood Chemical Analysis; D002273:Carcinogens / Q000493:pharmacokinetics / Q000633:toxicity*; D020111:Chlorodiphenyl (54% Chlorine); D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000097:blood; D005243:Feces / Q000737:chemistry*; D005260:Female; D007111:Immunity, Cellular / Q000187:drug effects; D008253:Macaca mulatta; D015999:Multivariate Analysis; D010060:Ovulation / Q000187:drug effects; D011166:Porphyrins / Q000652:urine; D011374:Progesterone / Q000097:blood; D011897:Random Allocation; D012627:Sebaceous Glands / Q000187:drug effects
D001140:Aroclors; D002273:Carcinogens; D004967:Estrogens; D011166:Porphyrins; D020111:Chlorodiphenyl (54% Chlorine); D011374:Progesterone